More Investment Sorely Needed to Combat Antimicrobial Resistance

Ryan Basen

November 10, 2021

Investors, pharma, advocates cite “market failure” in developing new treatments

WASHINGTON — Large pharmaceutical companies, investors, and other funders must increase investments to address antimicrobial resistance (AMR), and must do so now, experts and industry insiders said here this week.

However, most expressed skepticism that this will happen.

Speaking at the annual World AMR Congress, Greg Frank, PhD, director of global public policy for Merck, noted that “there’s very big challenges” in raising funds to address AMR…

Read the full article here.

Wall Street Journal

The World Needs New Antibiotics. The Problem Is, No One Can Make Them Profitably.

The push for antibiotics to fight fast-evolving superbugs is snagging on a broken business model. Six startups have won Food and Drug…

Fighting AMR with a value and subscription model

The recent reintroduction of the Pasteur Bill seeks to address the global threat that antimicrobial-resistant (AMR) infections pose, one subscription…

Scientists use AI to find new antibiotics, but can they climb out of the ‘valley of death’ to the clinic?

Developing a new antibiotic can take as long as 15 years. But in as few as two, the target bug…

‘The Last of Us’ might be fiction, but fungi are a looming threat

Fungal infections are a growing challenge for hospitalized patients, and new treatments are badly needed. A patient with leukemia undergoes…

Name
First Last
Email
Zipcode
Organization
Title
Comments
This field is for validation purposes and should be left unchanged.

MedPage Today

More Investment Sorely Needed to Combat Antimicrobial Resistance

Ryan Basen

November 10, 2021

Investors, pharma, advocates cite “market failure” in developing new treatments

More

Wall Street Journal

The World Needs New Antibiotics. The Problem Is, No One Can Make Them Profitably.

Pharmaceutical Technology

Fighting AMR with a value and subscription model

Fierce Biotech

Scientists use AI to find new antibiotics, but can they climb out of the ‘valley of death’ to the clinic?

PHARMAVOICE

‘The Last of Us’ might be fiction, but fungi are a looming threat

Sign up for the latest on fighting AMR